Irinotecan for pediatric solid tumors: The memorial Sloan-Kettering experience Academic Article Article uri icon

Overview

MeSH Major

  • Bone Neoplasms
  • Osteosarcoma

abstract

  • Irinotecan appears to have promising single-agent activity, particularly against rhabdomyosarcoma. with minimal hematopoietic toxicity, making it ideal for further evaluation in patients at high risk with newly diagnosed disease, particularly in combination with other active agents with nonoverlapping toxicities.

publication date

  • February 26, 2002

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1097/00043426-200202000-00009

PubMed ID

  • 11990694

Additional Document Info

start page

  • 101

end page

  • 5

volume

  • 24

number

  • 2